country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-189662

Copy Link Print Information

Y-U0-S

Y-U0-S is a potent inhibitor of the coronavirus main protease (M^pro) and host cathepsins. The IC₅₀ values of Y-U0-S against SARS-CoV-2 M^pro, SARS-CoV M^pro, Cathepsin B, and Cathepsin L are 0.81, 1.14, 0.86, and 21.13 μM, respectively. Y-U0-S exhibits broad-spectrum anti-coronavirus activity, with an EC₅₀ of 0.22 μM against wild-type SARS-CoV-2. Y-U0-S forms an irreversible covalent bond with the catalytic site C145 of M^pro through its aldehyde warhead, and by optimizing multi-site occupancy of the scaffold to engage conserved residues, it effectively blocks enzyme activity and inhibits viral replication. Y-U0-S can be used for research on COVID-19.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

화학식: C₂₅H₂₄ClFN₄O₃S
분자량:515.00

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

Y-U0-S Chemical Structure

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

^[1]

Cathepsin B

0.86 μM (IC₅₀)

cathepsin L

21.13 μM (IC₅₀)

SARS-CoV-2 Mpro

0.81 μM (IC₅₀)

SARS-CoV Mpro

1.14 μM (IC₅₀)

All Cathepsin Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Calu-3	EC₅₀	0.22 μM	Antiviral activity against wild-type SARS-CoV-2 in human lung epithelial Calu-3 cells assessed by immunofluorescence for spike expression on day 2 after infection. Antiviral activity against wild-type SARS-CoV-2 in human lung epithelial Calu-3 cells assessed by immunofluorescence for spike expression on day 2 after infection.	42679698
Calu-3	CC₅₀	34.4 μM	Cytotoxicity against mock-infected human lung epithelial Calu-3 cells by MTT assay after 2 days. Cytotoxicity against mock-infected human lung epithelial Calu-3 cells by MTT assay after 2 days.	42679698
Calu-3	EC₅₀	1.38 μM	Antiviral activity against SARS-CoV-2 Gamma variant in human lung epithelial Calu-3 cells assessed by immunofluorescence for spike expression on day 2 after infection. Antiviral activity against SARS-CoV-2 Gamma variant in human lung epithelial Calu-3 cells assessed by immunofluorescence for spike expression on day 2 after infection.	42679698
Calu-3	EC₅₀	1.49 μM	Antiviral activity against SARS-CoV-2 Delta variant in human lung epithelial Calu-3 cells assessed by immunofluorescence for spike expression on day 2 after infection. Antiviral activity against SARS-CoV-2 Delta variant in human lung epithelial Calu-3 cells assessed by immunofluorescence for spike expression on day 2 after infection.	42679698
Calu-3	EC₅₀	0.26 μM	Antiviral activity against SARS-CoV-2 Omicron variant in human lung epithelial Calu-3 cells assessed by immunofluorescence for spike expression on day 2 after infection. Antiviral activity against SARS-CoV-2 Omicron variant in human lung epithelial Calu-3 cells assessed by immunofluorescence for spike expression on day 2 after infection.	42679698
Calu-3	EC₅₀	1.19 μM	Antiviral activity against reverse genetically generated wild-type rgSARS-CoV-2 in human lung epithelial Calu-3 cells assessed by GFP expression on day 2 after infection. Antiviral activity against reverse genetically generated wild-type rgSARS-CoV-2 in human lung epithelial Calu-3 cells assessed by GFP expression on day 2 after infection.	42679698
Calu-3	EC₅₀	6.89 μM	Antiviral activity against reverse genetically generated SARS-CoV-2 Mpro T21I/E166V mutant in human lung epithelial Calu-3 cells assessed by GFP expression on day 2 after infection. Antiviral activity against reverse genetically generated SARS-CoV-2 Mpro T21I/E166V mutant in human lung epithelial Calu-3 cells assessed by GFP expression on day 2 after infection.	42679698
Calu-3	EC₅₀	3.52 μM	Antiviral activity against reverse genetically generated SARS-CoV-2 Mpro L50F/E166V mutant in human lung epithelial Calu-3 cells assessed by GFP expression on day 2 after infection. Antiviral activity against reverse genetically generated SARS-CoV-2 Mpro L50F/E166V mutant in human lung epithelial Calu-3 cells assessed by GFP expression on day 2 after infection.	42679698

In Vitro

Viral InfectionOthers

Viral Infection

Y-U0-S (2 days) inhibits wild-type SARS-CoV-2 in Calu-3 cells with an EC₅₀ of 0.22 μM and a CC₅₀ of 34.4 μM^[1].
Y-U0-S (2 days) maintains broad-spectrum antiviral activity against Gamma, Delta, Omicron, and Nirmatrelvir (HY-138687)-resistant M^pro mutants in Calu-3 cells, with EC₅₀ values ranging from 0.26 to 6.89 μM^[1].

Others

Y-U0-S exhibits inhibitory activity against SARS-CoV-2 M^pro, SARS-CoV M^pro, Cathepsin B, and Cathepsin L in recombinant protease systems, with IC₅₀ values of 0.81, 1.14, 0.86, and 21.13 μM^[1], respectively.
Y-U0-S inhibits the enzymatic activity of the Nirmatrelvir-resistant mutants M^pro (T211/E166V) and M^pro (L50F/E166V) in a recombinant protein system, with IC₅₀ values of 7.03 μM and 6.27 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

분자량 515.00
화학식 C₂₅H₂₄ClFN₄O₃S
SMILES

O=C(NCC1=CC=CS1)C(C2=CC(F)=CC(Cl)=C2)N3C[C@@H](C=O)N(C(C4=CN=CC(C)=C4)=O)CC3
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Handling Instructions (2659 KB)

References

[1]. Ye B, et al. Discovery of piperazine-based multi-site occupying coronavirus M inhibitors with potent and broad-spectrum antiviral activity. European journal of medicinal chemistry. 2026 Aug 22;319:119248.

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기